Clinical Trial Update: Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) [Phase 2]

View source ↗

Summary

This document reports an ongoing Phase 2 safety study of Anumigilimab (CSL324) in adults with Sickle Cell Disease, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Anumigilimab (CSL324)

Snippet

Sponsor: CSL Behring | Conditions: Sickle Cell Disease | Phase 2 | Status: RECRUITING